8-K: Neurocrine Biosciences Announces Positive Phase 2 Results for Schizophrenia Drug NBI-1117568

Neurocrine Biosciences reports positive top-line data from its Phase 2 clinical trial of NBI-1117568, a novel schizophrenia treatment, showing significant symptom reduction and good tolerability.

Summary

• Neurocrine Biosciences has announced positive results from its Phase 2 clinical trial for NBI-1117568, an investigational drug for schizophrenia.
• The study, named NBI-568-SCZ2028, was a dose-finding study that evaluated the efficacy and safety of NBI-568 in adults with schizophrenia.
• The 20 mg once-daily dose of NBI-568 met the primary endpoint, showing a statistically significant reduction in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6.
• The placebo-adjusted mean reduction was 7.5 points (p=0.011) with an effect size of 0.61, and an 18.2-point reduction from baseline was observed.
• The 20 mg dose also showed statistically significant improvements in other endpoints, including the Clinical Global Impression of Severity (CGI-S) scale and Marder Factor Scores for both positive and negative symptoms.
• NBI-568 was generally safe and well-tolerated across all doses tested, with similar treatment discontinuation rates due to adverse events compared to placebo.
• The most common adverse events were somnolence, dizziness, and headache, while gastrointestinal and cardiovascular events were low and similar to placebo.
• Notably, NBI-568 did not cause a greater increase in weight compared to placebo, and few extrapyramidal symptoms were reported.
• Neurocrine plans to advance NBI-568 into Phase 3 development in early 2025.
• The study enrolled 210 participants and was a multi-center, randomized, double-blind, placebo-controlled trial.

Sentiment

Score: 8

Explanation: The document presents very positive results from a Phase 2 trial, with strong efficacy and a good safety profile. The company is moving forward to Phase 3, which is a positive sign. There are some risks mentioned, but the overall tone is optimistic.

Positives

• NBI-1117568 demonstrated a statistically significant and clinically meaningful reduction in schizophrenia symptoms.
• The drug was well-tolerated with a safety profile similar to placebo.
• There was no significant weight gain associated with NBI-568.
• The drug is a novel M4 selective agonist, offering a new approach to treating schizophrenia.
• The once-daily dosing regimen is convenient for patients.
• The results support advancement to Phase 3 clinical trials.

Negatives

• The most common adverse events were somnolence, dizziness, and headache, although these were generally mild.
• Some patients experienced nausea and constipation, but these were similar to placebo rates.
• The study was conducted in an inpatient setting, which may not fully reflect real-world conditions.

Risks

• The reported top-line data may change after a more comprehensive review.
• Clinical development activities may be delayed or unsuccessful.
• Regulatory submissions may not occur or be submitted in a timely manner.
• The drug may not be as effective or safe in larger, more diverse populations.
• There are risks associated with dependence on third parties for development, manufacturing, and commercialization.
• The FDA or other regulatory authorities may make adverse decisions regarding the drug.
• The potential benefits of collaboration agreements may not be realized.
• The drug may be precluded from commercialization by the proprietary or regulatory rights of third parties.
• There are risks associated with potential generic entrants for the product.

Future Outlook

Neurocrine plans to advance NBI-568 into Phase 3 development in early 2025 and is evaluating additional indications for the drug. The company is also advancing other compounds in its muscarinic agonist portfolio.

Management Comments

• Eiry Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences, stated that the Phase 2 study delivered on the goal of identifying a once-daily, well-tolerated dosing regimen with a compelling benefit-risk profile.
• Dr. Maurizio Fava, Psychiatrist-in-Chief at Massachusetts General Hospital of Harvard University, noted that NBI-1117568 demonstrated a clinically meaningful and statistically significant reduction in PANSS scores and was well tolerated, with minimal GI effects and no weight gain relative to placebo.

Industry Context

The development of NBI-1117568 as a selective M4 agonist represents a novel approach in the treatment of schizophrenia, potentially offering an alternative to traditional antipsychotics with fewer side effects. This aligns with the industry's focus on developing more targeted and effective treatments for mental health disorders.

Comparison to Industry Standards

• The effect size of 0.61 for NBI-568 is comparable to some leading antipsychotics and other clinical-stage muscarinic programs.
• The study results are similar to the effect sizes seen in Phase 2 trials of KarXT (0.68) and Emraclidine (0.60).
• The 7.5 point placebo-adjusted reduction in PANSS score is a clinically meaningful improvement.
• The safety profile of NBI-568, with low rates of gastrointestinal issues and no weight gain, is a positive differentiator compared to some traditional antipsychotics.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Patients with schizophrenia may benefit from a new treatment option with a potentially improved safety profile.
• Employees of Neurocrine Biosciences may be motivated by the progress of the drug development program.
• The results may positively impact the company's reputation and standing in the biopharmaceutical industry.

Next Steps

• Neurocrine plans to advance NBI-568 into Phase 3 development in early 2025.
• The company will evaluate additional indications for NBI-568.
• Neurocrine will continue to advance other compounds in its muscarinic agonist portfolio.

Key Dates

Keywords

schizophrenia, NBI-1117568, muscarinic M4 agonist, clinical trial, Phase 2, PANSS, neuroscience, psychiatry, drug development, biopharmaceutical